

# Daniel Eiger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7123441/publications.pdf>

Version: 2024-02-01

18  
papers

365  
citations

1040056

9  
h-index

996975

15  
g-index

18  
all docs

18  
docs citations

18  
times ranked

554  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. <i>Cancers</i> , 2022, 14, 2596.   | 3.7 | 8         |
| 2  | Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2946-2956. | 1.6 | 46        |
| 3  | The Exciting New Field of HER2-Low Breast Cancer Treatment. <i>Cancers</i> , 2021, 13, 1015.  | 3.7 | 83        |
| 4  | Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.  | 2.8 | 33        |
| 5  | Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 510-510.  | 1.6 | 3         |
| 6  | Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. <i>Breast</i> , 2021, 57, 86-94.  | 2.2 | 6         |
| 7  | Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 462-470.   | 6.3 | 20        |
| 8  | Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer. <i>ESMO Open</i> , 2020, 5, e000688.  | 4.5 | 0         |
| 9  | Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. <i>British Journal of Cancer</i> , 2020, 122, 1453-1460.   | 6.4 | 22        |
| 10 | Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 199-209.   | 2.5 | 19        |
| 11 | The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). <i>Acta Oncologica</i> , 2020, 59, 723-725.   | 1.8 | 7         |
| 12 | Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. <i>ESMO Open</i> , 2020, 5, e000659.   | 4.5 | 6         |
| 13 | Pertuzumab in HER2-positive early breast cancer: current use and perspectives. <i>Future Oncology</i> , 2019, 15, 1823-1843.  | 2.4 | 14        |
| 14 | Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. <i>Annals of Oncology</i> , 2019, 30, x27-x42.   | 1.2 | 63        |
| 15 | Complete lymphadenectomy following positive sentinel lymph node biopsy in cutaneous melanoma: a critical review. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 553-558.  | 1.1 | 8         |
| 16 | Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center. <i>BMC Palliative Care</i> , 2018, 17, 13.   | 1.8 | 27        |
| 17 | Experience with palliative sedation (PS) in an inpatient oncology setting. <i>Journal of Clinical Oncology</i> , 2016, 34, e21503-e21503.   | 1.6 | 0         |
| 18 | Experience with palliative sedation (PS) in an inpatient oncology setting. <i>Journal of Clinical Oncology</i> , 2016, 34, 63-63.   | 1.6 | 0         |